Piramal Pharma Q2FY27 Revenue Up 28% to ₹2,617 Crore, EBITDA Soars 72%
Piramal Pharma reported Q2FY27 consolidated revenue of ₹2,617 crore (up 28% YoY) and H1FY27 revenue of ₹4,887 crore (up 23% YoY). EBITDA surged 72% YoY to ₹385 crore in Q2FY27. The company upgraded its FY27 revenue growth outlook to 19-20% with higher profitability.
The announcement details significant financial performance improvements across all business segments and an upgraded future outlook, which are material events for investors and stakeholders.
The company reported strong year-on-year growth in revenue and a significant increase in EBITDA, along with an upgraded financial outlook for FY27. This indicates a positive financial performance and positive future prospects.
Piramal Pharma Limited (PPL) announced its unaudited financial results for the second quarter (Q2) and half year (H1) ended September 30, 2026. The company reported a consolidated revenue from operations of ₹2,617 crore for Q2FY27, marking a 28% year-on-year increase. For H1FY27, revenue grew by 23% YoY to ₹4,887 crore. EBITDA saw a significant jump of 72% YoY in both Q2FY27 and H1FY27, reaching ₹385 crore and ₹669 crore, respectively. This substantial improvement in profitability was driven by higher capacity utilization, operating leverage, disciplined execution, and cost optimization initiatives, leading to an expansion in EBITDA margin by over 350 basis points in both periods.
The Contract Development and Manufacturing Organization (CDMO) business demonstrated robust growth, with revenue increasing by 36% YoY in Q2FY27 and 28% YoY in H1FY27, supported by strong commercial demand, improved execution, and disciplined cost management. The Complex Hospital Generics (CHG) business also performed well, with revenue up by 32% YoY in Q2FY27 and 24% YoY in H1FY27, driven by strong inhalation anesthesia sales in ex-US markets and the integration of Kenalog®. Piramal Consumer Healthcare (PCH) reported a 13% YoY revenue growth in Q2FY27 and 14% YoY in H1FY27, with Power Brands and e-commerce channels being key contributors.
Based on the strong first-half performance and continued business momentum, Piramal Pharma has upgraded its FY27 outlook. The company now expects revenue growth of 19% to 20% for FY27, accompanied by meaningfully higher profitability. The company will be hosting an earnings conference call on October 28, 2026, from 10:00 AM to 10:45 AM (IST) to discuss its Q2 and H1 FY2027 results.
What to do with a filing like this
Piramal Pharma Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Piramal Pharma Limited. Read the original for the full detail.